We are live on ! Find out more
HUMA icon

Humacyte

28 hedge funds and large institutions have $30.9M invested in Humacyte in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 9

22% more funds holding

Funds holding: 2328 (+5)

18% more capital invested

Capital invested by funds: $26.2M → $30.9M (+$4.72M)

5.94% more ownership

Funds ownership: 23.31%29.25% (+5.9%)

50% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 6

Holders
28
Holders Change
+5
Holders Change %
+21.74%
% of All Funds
0.49%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
14
Increased
3
Reduced
6
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of America
26
Bank of America
North Carolina
$5K +$5.15K +500 New
Morgan Stanley
27
Morgan Stanley
New York
$2K -$567 -55 -22%
HR
28
Howe & Rusling
New York
$2K +$2.06K +200 New
Marshall Wace
29
Marshall Wace
United Kingdom
-$494K -45,590 Closed
NM
30
Newtyn Management
New York
-$437K -40,333 Closed
Jane Street
31
Jane Street
New York
-$298K -27,558 Closed
SSA
32
Schonfeld Strategic Advisors
New York
-$178K -16,481 Closed
DTL
33
Dynamic Technology Lab
Singapore
-$130K -12,041 Closed
FHC
34
First Heartland Consultants
Missouri
-$118K -10,925 Closed
Royal Bank of Canada
35
Royal Bank of Canada
Ontario, Canada
-$8K -715 Closed
Rockefeller Capital Management
36
Rockefeller Capital Management
New York
-$5K -500 Closed
VFA
37
Valeo Financial Advisors
Indiana
-$4K -400 Closed

HUMA Hedge Fund Activity: Q2 2021 in Review

28 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q2 2021, worth a combined $30.9M — up 18% from $26.2M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new HUMA positions and 9 closed out — a net gain of 5 holders — while 3 added to existing stakes and 6 trimmed.

The largest buyer was Altium Capital Management, opening a new position worth an estimated $2.83M. The largest seller was Alpine Global Management, cutting an estimated $3.21M.

  • 28 institutional investors held Humacyte (HUMA) as of Q2 2021, up from 23 in Q1 2021.
  • Funds reported $30.9M of Humacyte stock for Q2 2021, up 18% quarter-over-quarter.
  • 14 funds opened new Humacyte positions in Q2 2021 and 9 closed out, a net change of +5 holders.
  • The largest Humacyte buyer in Q2 2021 was Altium Capital Management, an estimated $2.83M added.
  • The largest Humacyte seller in Q2 2021 was Alpine Global Management, an estimated $3.21M sold.

Based on aggregated 13F filings for Q2 2021.